US2019117747A1PendingUtilityA1
Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans
Assignee: THE HENRY M JACKSON FOUND FOR THE ADVANCEMEN OF MILITARY MEDICINE INCPriority: Nov 20, 2013Filed: Dec 14, 2018Published: Apr 25, 2019
Est. expiryNov 20, 2033(~7.3 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 37/06A61K 39/39A61K 39/0008A61K 39/35A61K 35/62A61K 2039/55516A61K 39/0003A61P 11/02Y02A50/30
31
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of using axenic C. elegans homogenate for treating allergies or an autoimmune disease are disclosed. Also disclosed is a composition comprising a homogenate of C. elegans, wherein the homogenate is obtained from C. elegans cultured in axenic media, for use in treating an allergy or autoimmune disease.
Claims
exact text as granted — not AI-modified1 . A method of treating an allergy or an autoimmune disease in a subject, the method comprising administering to the subject an effective amount of a composition comprising a homogenate of C. elegans, wherein the homogenate is obtained from C. elegans cultured in axenic media that is free of E. coli.
2 . The method of claim 2 , wherein the autoimmune disease is a Th1-mediated autoimmune disease.
3 . The method of claim 3 , wherein the Th1-mediated autoimmune disease is selected from type 1 insulin-dependent diabetes mellitus, scleroderma, multiple sclerosis, posterior uveitis, Crohn's disease, inflammatory bowel disease, and rheumatoid arthritis.
4 . The method of claim 3 , wherein the Th1-mediated autoimmune disease is type 1 insulin-dependent diabetes mellitus.
5 . The method of claim 1 , wherein the allergy is an environmental allergy or asthma.
6 . The method of claim 1 , wherein the subject is a mammal.
7 . The method of claim 1 , wherein the subject is a human.
8 . The method of claim 1 , wherein the composition is administered chronically to the subject.
9 . The method of claim 1 , wherein the composition is administered orally, parentally, or subcutaneously.
10 . The method of claim 1 , wherein the composition is free of E. coli endotoxins.
11 . The method of claim 10 , wherein the composition is free of lipopolysaccharides.
12 . (canceled)
13 . (canceled)
14 . A homogenate of C. elegans and a pharmaceutically acceptable excipient, wherein the homogenate is obtained from C. elegans cultured in axenic media that is free of E. coli.
15 . A method of increasing levels of IL-10 in a subject having a Th1-mediated autoimmune disease, the method comprising administering to the subject an effective amount of a composition comprising a homogenate of C. elegans, wherein the homogenate is obtained from C. elegans cultured in axenic media that is free of E. coli.
16 . The method of claim 15 , wherein the Th1-mediated autoimmune disease is type 1 insulin dependent diabetes mellitus.
17 . The method of claim 15 , wherein the subject is a mammal.
18 . The method of claim 15 , wherein the subject is a human.
19 . The method of claim 15 , wherein the composition is administered chronically to the subject.
20 . The method of claim 15 , wherein the composition is administered orally, parentally, or subcutaneously.
21 . The method of claim 15 , wherein the composition is free of E. coli endotoxins.
22 . The method of claim 15 , wherein the composition is free of lipopolysaccharides.Join the waitlist — get patent alerts
Track US2019117747A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.